ReviewFuture oncology (London, England)2008
Combating immunosuppression in glioma.
Review in Future oncology (London, England), 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 1 synthesis or guideline pooled it, 64 citations in OpenAlex.
- Bone metastasis from glioblastoma: a systematic review.Journal of neuro-oncology · 2022Pooled it
- Microglia Reprogramming in Glioblastoma: Stem Cell-Derived Factors as Emerging Immunomodulators.Cells · 2026Review
- Cytomegalovirus-induced oncomodulation drives immune escape in glioblastoma.Scientific reports · 2025Article
- Understanding the Immune System and Biospecimen-Based Response in Glioblastoma: A Practical Guide to Utilizing Signal Redundancy for Biomarker and Immune Signature Discovery.Current oncology (Toronto, Ont.) · 2024Review
- Review
- A TGF-β signaling-related lncRNA signature for prediction of glioma prognosis, immune microenvironment, and immunotherapy response.CNS neuroscience & therapeutics · 2024Article
- T cell exhaustion in malignant gliomas.Trends in cancer · 2023Review
- Understanding the relationship between gliomas and T cells: Paving the way for effective immunotherapy.Neuro-oncology · 2022Article
- HOXA-AS2 contributes to regulatory T cell proliferation and immune tolerance in glioma through the miR-302a/KDM2A/JAG1 axis.Cell death & disease · 2022Article
- The Involvement of Long Non-Coding RNAs in Glioma: From Early Detection to Immunotherapy.Frontiers in immunology · 2022Review
- Mechanisms of Long Non-Coding RNAs in Biological Characteristics and Aerobic Glycolysis of Glioma.International journal of molecular sciences · 2021Review
- Activation of 4-1BBL+ B cells with CD40 agonism and IFNγ elicits potent immunity against glioblastoma.The Journal of experimental medicine · 2021Article
- Advances in radiotherapy and comprehensive treatment of high-grade glioma: immunotherapy and tumor-treating fields.Journal of Cancer · 2021Review
- Brain cancer induces systemic immunosuppression through release of non-steroid soluble mediators.Brain : a journal of neurology · 2020Article
- Article
- Immune Escape in Glioblastoma Multiforme and the Adaptation of Immunotherapies for Treatment.Frontiers in immunology · 2020Review
- Roles of Extracellular Vesicles in High-Grade Gliomas: Tiny Particles with Outsized Influence.Annual review of genomics and human genetics · 2019Review
- Low-dose irradiated mesenchymal stromal cells break tumor defensive properties in vivo.International journal of cancer · 2018Article
- Optimizing EphA2-CAR T Cells for the Adoptive Immunotherapy of Glioma.Molecular therapy. Methods & clinical development · 2018Article
- Hacking macrophage-associated immunosuppression for regulating glioblastoma angiogenesis.Biomaterials · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Despite maximal therapy, malignant gliomas have a very poor prognosis. Patients with glioma express significant immune defects, including CD4 lymphopenia, increased fractions of regulatory T cells in peripheral blood and shifts in cytokine profiles from Th1 to Th2. Recent studies have focused on ways to combat immunosuppression in patients with glioma as well as in animal models for glioma. We concentrate on two specific ways to combat immunosuppression: inhibition of TGF-beta signaling and modulation of regulatory T cells. TGF-beta signaling can be interrupted by antisense oligonucleotide technology, TGF-beta receptor I kinase inhibitors, soluble TGF-beta receptors and antibodies against TGF-beta. Regulatory T cells have been targeted with antibodies against T-cell markers, such as CD25, CTLA-4 and GITR. In addition, vaccination against Foxp3 has been explored. The results of these studies have been encouraging; combating immunosuppression may be one key to improving prognosis in malignant glioma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.